Global Radiodermatitis Market is estimated to be valued at US$ 407.2 million in 2023 and is expected to exhibit a CAGR of 4.3 % during the forecast period (2023-2030).
Analysts’ views on Global Radiodermatitis Market:
A skin condition that is a common side effect of radiation therapy. The affected skin becomes painful, red, itchy, and blistered. Radiation-induced dermatitis (RID) is a very common side effect that is almost universally experienced by patients undergoing radiotherapy (RT) for cancer treatment. RID results from cutaneous or subcutaneous lesions due to external beam radiation. Radiodermatitis is a skin condition in which the skin becomes dry, itchy and inflamed, causing redness, swelling, scaling and peeling. Radiodermatitis is the body's reaction to ionizing radiation given to cancer patients and in imaging techniques. It is also known as X-ray rash, radiation dermatitis, radiation skin reactions or radiation damage. Nuclear attacks and disasters can also cause the condition.
Figure 1. Global Radiodermatitis Market Share (%), By Product Type, 2023
Global Radiodermatitis Market– Drivers
Increasing Research and Development Activities in Radiodermatitis
Increasing research and development in the field of radiodermatitis is expected to drive the global radiodermatitis market growth over the forecast period. For instance, on October 29, 2021, an article published by Cleveland Clinic, U.S. summarised the study's findings, saying that doctors might advise using creams to treat symptoms such as dry, itchy skin. They may also prescribe special creams to treat severe radiation dermatitis or radiation burns. For example, a steroid cream may be prescribed by doctor if are receiving treatment for breast cancer in order to lower risk of developing radiation dermatitis. Before using a cream or other moisturiser, see doctor. They will explain which creams to use and which ones are safe.
Figure 2. Global Radiodermatitis Market Value (US$ Million), By Region, 2023
Global Radiodermatitis Market - Regional Analysis
Among region, North America is estimated to hold a dominant position in the global radiodermatitis market over the forecast period, owing to increasing treatment for radiodermatitis. For instance, on May 17, 2023, MJH Life Sciences, U.S. based publishing company, published an article explaining Prophylaxis with antibacterial topical treatment may reduce acute radiation dermatitis severity. 2./3. according to the findings of the phase II trial, none of the patients who received antibacterial treatment developed moist scaling, the most severe form of acute radiation dermatitis that ends in skin breakdown, even though more than half of the patients had mild to moderate acute radiation dermatitis. Ulcers develop. 23.7% of individuals in the control group experienced severe acute radiation dermatitis. The antibacterial regimen included twice-daily application of 2% mupirocin nasal ointment and 4% chlorhexidine gluconate body wash for five days before to radiotherapy and continued every other week throughout treatment.
Global Radiodermatitis Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding the transportation of drugs from one place to another.
However, the COVID-19 pandemic has impacted the global radiodermatitis market. For instance, on March 23, 2023, an article published by Springer explained comparing studies of breast cancer patients with studies that included both breast and head and neck cancer studies, photobiomodulation therapy was found to be protective against low-grade or no disease. Study discontinuations were more common in the photobiomodulation therapy groups, with "insufficient assessments" and the COVID-19 pandemic cited as the main reasons for discontinuation.
Radiodermatitis Market Report Coverage
|Market Size in 2023:
|US$ 407.2 Mn
|Historical Data for:
|2018 to 2021
|2023 to 2030
|Forecast Period 2023 to 2030 CAGR:
|2030 Value Projection:
|US$ 546.5 Mn
Acelity, Inc. (3M)BMG Pharma S.r.l., ConvaTec Group PLC, DermaSciences Inc. (Integra LifeSciences Holdings Corporation), Intermed Pharmaceuticals, Mölnlycke Health Care, Smith & Nephew Plc, Stratpharma AG, Kannalife, Inc., McKesson Corporation.
|Restraints & Challenges:
Global Radiodermatitis Market Segmentation:
Global Radiodermatitis Market report is segmented into product type, distribution channel, and region.
Based on Product Type, the global radiodermatitis market is segmented into Topical Agents, Oral Medication, dressing. Out of which, Topical Agents segment is expected to dominate the market due to increasing launch of products.
Based on distribution channels, the hospital pharmacies is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Among these, the hospital pharmacies segment is expected to dominate the market over the forecast period, owing to increasing treatments and medicines.
Based on Region, the global radiodermatitis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East & Africa. Among these, North America is expected to dominate the market over the forecast period due to increased research and development activities.
Global Radiodermatitis Market Cross Sectional Analysis:
Introduction of newer treatments of radiodermatitis in North America region is expected to drive growth of product type segment in the region. For instance, on June 12, 2020, an article published by National Center for Biotechnology Information, explained the treatment as Silver sulfadiazine, a topical antibacterial drug, is used as an ointment for second and third-degree burns. This molecule also has anti-inflammatory properties and functions to repair the protective layer that helps protect the skin from infectious agents. In a preliminary study, the use of a dressing containing silver sulfadiazine was associated with the overall severity of radiation-induced dermatitis. Similar findings have been reported with silver nylon dressings or Mepilex Foam Lite dressings.
Global Radiodermatitis Market: Key Developments
On May 4, 2023, Albert Einstein College of Medicine, U.S explained a simple antibacterial treatment solves a severe skin problem caused by radiation therapy, Staphylococcus aureus (SA), often shortened to "staph", usually lives harmlessly on the skin, often in the nose and armpits. But they can cause infections if the skin of the incision breaks. Radiation weakens the skin structure at the treatment site and can cause infection, allowing SA to penetrate the outer layer of the skin.
On September 15, 2022, BMG Pharma, Italy based pharmaceutical company and HTL Biotechnology, France based biotechnology company signed an agreement for the production of the functional ingredient underlying the patented Hyaluromimethic technology works on Sodium Hyaluronate Lipoate Formate (SHLF) to develop solutions in aesthetic dermatology, ophthalmology, and arthrosis. SHLF’s properties including improved resistance to enzymatic degradation, self-crosslinking properties, and elastic modulus are of great interest in dermo-aesthetic and osteoarthritis medicine.
Global Radiodermatitis Market: Key Trends
Introduction of newer application of drugs
Introduction of application of drugs can drive the growth of the market. For instance, on June 12, 2020, an article published by the National Center for Biotechnology Information ( NCBI ) as Trolamine is widely used in the treatment of RID because it is believed to act as a nonsteroidal anti-inflammatory molecule. However, several randomized controlled trials have not shown an advantage of trolamine over supportive care or even placebo in the treatment of RD.Recently, doxepin cream has been shown to suppress skin inflammation when used after RT in breast cancer patients.
Global Radiodermatitis Market: Restraints
Risk related to radiodermatitis
The risk of developing radiation-induced dermatitis depends on several factors related to treatment: the dose of radiation during one delivery, the total dose, the duration of exposure, the volume of the treated area, and the combination with other treatments, such as chemotherapy. In addition. , radiation-induced dermatitis may be influenced by patient-related factors such as high body mass index (BMI), smoking, nutritional status, pre-existing skin conditions such as psoriasis, and genetic predisposition.
To counterbalance this restrain, more awareness among personnel should be created regarding radiodermatitis.
Global Radiodermatitis Market - Key Players
Major players operating in the global radiodermatitis market include Acelity, Inc. (3M), BMG Pharma S.r.l., ConvaTec Group PLC, DermaSciences Inc. (Integra LifeSciences Holdings Corporation), Intermed Pharmaceuticals, Mölnlycke Health Care, Smith & Nephew Plc., Stratpharma AG, Kannalife, Inc., McKesson Corporation.
*Definition: Radiodermatitis is a skin condition in which the skin becomes dry, itchy and inflamed, causing redness, swelling, scaling, and peeling. Radiodermatitis is the body's reaction to ionizing radiation given to cancer patients and in imaging techniques It is also referred to as radiation damage, radiation skin responses, radiation dermatitis, and X-ray rash. Disasters and nuclear assaults may also contribute to the condition. X-ray rash, radiation dermatitis, radiation skin responses, or radiation damage are other names for radiation dermatitis. is a side effect of external ionizing radiation. Radiation therapy, used to treat cancer or other diseases, is a leading cause of radiation dermatitis. Nuclear attacks and disasters can also cause the condition. The distribution channel includes retail pharmacies and online pharmacies.
Frequently Asked Questions